1. Is ICER NICEr?

   • Deborah Freund
   • Jennifer Choi

   Editorial 21 February 2018 Pages: 385 - 386

2. Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Robert Hodgson
   • Matthew Walton
   • Nerys Woolacott

   Review Article 30 November 2017 Pages: 387 - 398

   

3. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Hema Mistry
   • Chidozie Nduka
   • James Mason

   Review Article Open access 08 December 2017 Pages: 399 - 406

   

4. The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)

   • Salah Ghabri
   • Erwan Autin
   • Jean Michel Josselin

   Review Article 15 December 2017 Pages: 407 - 417

   

5. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis

   • Ewa Stawowczyk
   • Paweł Kawalec

   Systematic Review Open access 19 December 2017 Pages: 419 - 434

   

6. Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review

   • Dolly Han
   • Nicolas Iragorri
   • Eldon Spackman

   Systematic Review 19 January 2018 Pages: 435 - 449

   

7. Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index–9 Dimension (CHU-9D) Score for Economic Evaluation in Children

   • Tosin Lambe
   • Emma Frew
   • On behalf of the PREDNOS Trial Team

   Original Research Article 20 December 2017 Pages: 451 - 465

   

8. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017

   • Chris Skedgel
   • Dominika Wranik
   • Min Hu

   Original Research Article Open access 20 January 2018 Pages: 467 - 475

   

9. Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia

   • Axel C. Mühlbacher
   • Andrew Sadler
   • Christin Juhnke

   Original Research Article 31 January 2018 Pages: 477 - 493

   

10. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

    • Josh J. Carlson
    • Kangho Suh
    • William Wong

    Original Research Article 27 February 2018 Pages: 495 - 504

    

11. Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

    • Amir Ansaripour
    • Carin A. Uyl-de Groot
    • W. Ken Redekop

    Author Correction 23 February 2018 Pages: 505 - 505

12. Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal

    • Irina A. Tikhonova
    • Tracey Jones-Hughes
    • Martin Hoyle

    Correction 24 February 2018 Pages: 507 - 507